Arrhythmia Treatment Medical Devices sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Arrhythmia Treatment Medical Devices
1.1 - About Arrhythmia Treatment Medical Devices sector
Companies in Arrhythmia Treatment Medical Devices design and manufacture systems that diagnose, monitor, and correct abnormal heart rhythms. For M&A teams evaluating strategic buyers in cardiac care, these vendors offer portfolios of implantable and external technologies that restore conduction, prevent sudden cardiac death, and support clinical decision-making. By pairing device hardware with software-enabled monitoring and analytics, they help providers deliver safer, more effective rhythm management across care settings.
They develop pacemakers and implantable cardioverter‑defibrillators to deliver precise pacing and life‑saving shocks, offer cardiac resynchronization therapy systems for dyssynchronous heart failure, and supply electrophysiology ablation catheters guided by 3D electroanatomic mapping. Many provide implantable loop recorders for long‑term rhythm surveillance, wearable ECG and Holter solutions for ambulatory monitoring, and secure remote monitoring platforms that integrate with EHRs, device clinics, and analytics tools to automate alerts, compliance tracking, and longitudinal outcomes reporting.
Primary customers include hospital cardiology departments, electrophysiology labs, and integrated health systems that manage device clinics. These buyers seek improved patient survival and quality of life, lower readmissions for atrial fibrillation and heart failure, and greater procedural efficiency in EP suites. Vendors also enable better data governance and reimbursement compliance through remote monitoring and documentation, helping systems scale rhythm management programs while reducing total cost of care.
2. Buyers in the Arrhythmia Treatment Medical Devices sector
2.1 Top strategic acquirers of Arrhythmia Treatment Medical Devices companies
AtriCure
- Description: Provider of medical device technologies for treating atrial fibrillation and related complications, delivering FDA-approved ablation, left atrial appendage exclusion, hybrid therapy and cryoablation solutions used by electrophysiologists and cardiothoracic surgeons worldwide to improve outcomes and manage post-operative pain.
- Key Products:
- Isolator Synergy Clamps: Bipolar RF surgical clamps that ablate cardiac tissue, creating isolation lesions to treat persistent atrial fibrillation during concomitant coronary bypass or valve repair procedures
- AtriClip LAA Exclusion System: Implantable clip applied under direct visualization to occlude the left atrial appendage during cardiac surgery, eliminating blood flow and lowering stroke risk
- EPi-Sense Coagulation Device: Epicardial RF device used in hybrid convergent procedures to deliver linear lesions for long-standing persistent atrial fibrillation when combined with specified endocardial catheters
- cryoSPHERE Cryoablation Probes: Single-use probes that freeze peripheral or intercostal nerves producing temporary nerve blocks, providing non-opioid post-surgical pain relief for adult and adolescent patients.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
2.2 - Strategic buyer groups for Arrhythmia Treatment Medical Devices sector
M&A buyer group 1: Smart ECG Monitoring Devices
AliveCor
- Type: N/A
- Employees: ●●●●●
- Description: Provider of FDA-cleared mobile electrocardiogram solutions, offering portable ECG recorders, companion mobile apps and educational services that let consumers and clinicians record, store, share and interpret heart-rhythm data via smartphones and secure cloud storage for proactive cardiac care.
- Key Products:
- EHR Integration: Automatically imports hospital- or home-recorded ECGs into EHRs like GE MUSE NX, maintaining workflows and providing cardiac data without manual transfer
- AliveCor SDK: Embeds KardiaMobile 6L recording in iOS/Android apps, connects to the device, displays waveforms, uses FDA-cleared AI for rhythm classification, and outputs raw data or PDFs, cutting dev time and regulatory effort
- AliveCor API: REST-based cloud API offers patient administration, webhook ECG alerts
- HIPAA-secure keys, and delivers PDFs or raw time-series ECGs directly into enterprise systems
- KardiaMobile 6L-GE MUSE NX Integration: Demonstrates six-lead portable device feeding ECGs straight into GE’s cardiac information system, giving clinicians immediate access without separate portals.
Buyer group 2: ████████ ████████
●● companiesBuyer group 3: ████████ ████████
●● companies3. Investors and private equity firms in Arrhythmia Treatment Medical Devices sector
3.1 - Buyout funds in the Arrhythmia Treatment Medical Devices sector
2.2 - Strategic buyer groups for Arrhythmia Treatment Medical Devices sector
4 - Top valuation comps for Arrhythmia Treatment Medical Devices companies
4.2 - Public trading comparable groups for Arrhythmia Treatment Medical Devices sector
Valuation benchmark group 1: Cardiovascular and Electrophysiology Device Manufacturers
Boston Scientific
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of innovative medical solutions, developing and manufacturing medical devices for interventional medical specialties including cardiology, oncology, endoscopy, and neuromodulation, aimed at improving patient health and transforming lives worldwide.
- Key Products:
- Cardiac Devices: Devices for diagnosing and treating heart conditions including stents, pacemakers, and defibrillators
- Oncology Solutions: Minimally invasive medical devices for diagnosing and treating various cancers
- Endoscopy Devices: Tools for diagnosing and treating gastrointestinal and pulmonary conditions
- Neuromodulation Devices: Electronic implantable technologies for managing chronic pain and neurological disorders
- Peripheral Intervention Devices: Technologies for treating peripheral artery and vein conditions.